Emerging Pharmacotherapy Landscape for MASLD and MASH

This narrative review synthesizes late-stage clinical data on seven drug classes for metabolic dysfunction-associated steatotic liver disease, giving endocrinology and obesity pharmacists a comparative framework for drug selection and drug-interaction counseling.

resmetiromsemaglutidetirzepatidesurvodutideefruxiferminpegozafermindenifanstatlanifibranorGLP-1 receptor agonistsFGF-21 analoguesTHR-beta agonistspan-PPAR agonistsFASN inhibitorsMASLDMASHnarrative reviewhepatologyobesity Endocrinology / Diabetes / Obesity

Background Information

Innovative treatments for MASLD target diverse pathways.

Metabolic-associated steatotic liver disease (MASLD) is an increasingly common condition with significant morbidity, making new treatments valuable for patient care. Resmetirom is the first approved drug for MASLD with various new agents like THR-β Agonists and FGF-21 Analogues in late-stage development. Pharmacists should be aware of the diverse mechanisms of these emerging therapies and consider patient-specific factors for treatment decisions and combination strategies. New pharmacotherapies for MASLD offer multiple mechanisms and potential combination benefits.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Straatmijer T, Mulder M

Citation: Straatmijer T, Mulder M New therapeutic options for metabolic-associated steatotic liver disease. British journal of clinical pharmacology. 2026. doi:10.1002/bcp.70795

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →